Program
tofersen
Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Biogen.
Furthest: phase 4, since Oct 31, 20255 company-led studies, 2 open or runningNext primary completion: May 26, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 52 open or running | phase 4since Oct 31, 2025 | Nov 24, 2015 | May 26, 2027phase 4 · NCT07223723 |
Also a collaborator on its studies: Ionis Pharmaceuticals.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2015First study: phase 3 study in Amyotrophic Lateral SclerosisFirst studyNCT02623699 · 176 enrolled · United States, Australia, Belgium and more
- Feb 28, 2017Phase 3 study in ALS Caused by Superoxide Dismutase 1 (SOD1) MutationNCT03070119 · 139 enrolled · United States, Belgium, Canada and more
- Dec 3, 2018Phase 1 study in Healthy VolunteersNCT03764488 · 8 enrolled · United States
- Apr 20, 2021Phase 3 study in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982 · 158 enrolled · United States, Australia, Belgium and more
- Oct 31, 2025Phase 4 study in Amyotrophic Lateral SclerosisNCT07223723 · 12 enrolled · China
Ahead
- May 26, 2027Primary completion: phase 4 study in Amyotrophic Lateral SclerosisNCT07223723
- Aug 7, 2027Primary completion: phase 3 study in Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223723Amyotrophic Lateral Sclerosis · China | 4 | Active, not recruiting | May 26, 2027 | 12 |
| NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation · United States, Australia, Belgium and more | 3 | Active, not recruiting | Aug 7, 2027 | 158 |
| NCT03764488Healthy Volunteers · United States | 1 | Completed | Jun 10, 2021 | 8 |
| NCT03070119ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation · United States, Belgium, Canada and more | 3 | Completed | Aug 12, 2024 | 139 |
| NCT02623699Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more | 3 | Completed | Jul 16, 2021 | 176 |
How it is read
Names in the registry
- “Tofersen”, 5 entries
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.